Life Sciences & Healthcare Innovation Hub

whirling blurry lights
Our innovation hub for life sciences and healthcare is a demonstration of Cooley’s enduring commitment to the industry. It serves as a centralized point from which to access the insights and unparalleled experience of leading legal thinkers from across the firm and around the world.
  • Laying the Right Foundations for Academic-Biotech Dealmaking  

    In Vivo

    Sublicensing rights, revenue considerations, licensed know-how and diligence milestones: getting these elements right in deals with academic institutions sets the tone for biotechs as they grow and seek partnering opportunities with big pharma.


  • What to Watch as EU Clinical Trial Compliance Changes  

    Law360

    It’s important for industry to consider reporting requirements not just in the US, but also for the European Union, given the Clinical Trials Regulation – which will go into effect in January 2022 and will impose an obligation on trials sponsors to publish amplified trial results in the Clinical Trials Information System database.


  • ×
  • IGNITE Fire Pitch Competition  

    Cooley is a proud sponsor of Ignite Healthcare Network’s Fire Pitch Grand Final Competition – a high-energy annual pitch competition event where finalists from women-led medtech and digital health companies pitch to compete for investment prizes in front of an audience of respected healthcare executives and investors.


  • Digital Health Innovation Summit – West  

    Cooley is the lead sponsor of the inaugural Digital Healthcare Innovation Summit – West, which is a two-day forum for the top innovators, investors, payers, providers and policymakers driving the digital health revolution.


  • Preparing for and Winning Medical Device Patent Litigation  

    Life Sciences & Healthcare Innovation Program

    Cooley IP litigators provide guidance to help your company prepare for and prevail in patent litigation in the medical device and diagnostics field – including best practices for offensive and defensive litigation matters, as well as thoughts on navigating transactions during pending litigation.


  • Biotech + Breaking Glass: Leading Women in Life Sciences  

    Life Sciences & Healthcare Innovation Program

    This installment features Clare Ozawa, managing director at Versant Ventures, a leading healthcare venture capital firm that has $4.2 billion under management and is committed to helping exceptional entrepreneurs build the next generation of great companies. Clare is joined by Cooley partners Madison Jones and Courtney Thorne, and they discuss topics around her role at Versant and her exceptional career to date.


  • Launch Strong: Strategies for Enforcing and Protecting Brands Prior to Commercialization  

    Life Sciences & Healthcare Innovation Program

    Don’t wait until product launch to take steps to strengthen and protect the mark from potential infringers, counterfeiters, and future litigants. This presentation will cover tools and cost-effective strategies for enforcing and strengthening potential trademarks prior to launch.


  • Digital Health Investment Trends & 2022 Outlook  

    Life Sciences & Healthcare Innovation Program

    In this Cooley Healthtech Talks webinar, leading venture capitalists give their digital health investments trends and predictions for 2022, and share their investment outlook and advice for entrepreneurs who are fundraising.


  • Trademark Law in 2021: Practical Trademark Perspectives from US and Canadian Counsel  

    During this program, a panel of thought leaders and professionals brought together by The Knowledge Group will guide you through recent developments in US trademark laws and notable court rulings.


  • Medical Device Investing 101  

    Presented by Alamo Angels and Biomed SA

    In this session, Carl Grant, executive vice president of global business development at Cooley, moderated a panel that featured Cooley lawyers Joshua Holleman and Kassity Mai. The program included a presentation on what to look for in a patent portfolio, and a discussion where company-side and investor-side leaders shared their unique perspectives on the benefits and risks of investing in a medical device startup.


  • WEBINAR<br>The Impact of Foreign Investment Screening Regimes on M&A Transactions  

    A Focus on the New UK Regime, with Key Learnings from  the US CFIUS Regime
    Previously Recorded

    This webinar covered the impact of the UK National Security and Investment Act 2021, which will come fully into force in January 2022, as well as recent developments in the Committee on Foreign Investment in the United States regime, and the implications for M&A transactions.


  • Venture Capital & Private Equity Conference Series  

    Session Four

    This series was led by industry thought leaders from Cooley and PwC and covered tax, audit, legal and other relevant topics for finance and legal professionals at venture capital and private equity funds.


  • Hatch-Waxman 101: Pre-Suit Investigation and&nbsp;Diligence  

    This program was targeted at innovative life science companies that have filed, or will soon file, NDA or 505(b)(2) applications and are anticipating their first Hatch-Waxman litigation.


  • Reimagining a Post-Pandemic Workplace  

    Previously Recorded

    Employers under pressure to create and implement return-to-work policies and procedures need to consider where they are going before they decide how to get there – and this webinar provides a structured way to think through these issues while preparing for the future of your workplace.


  • Four New Years – Life Science Policy in the Biden-Harris Era  

    Life Sciences & Healthcare Innovation Program – Previously Recorded

    A discussion of the key issues, priorities and people shaping the life science policy and regulatory landscape in Washington, DC.


  • Hatch-Waxman 101 for the Emerging Life Science Company  

    Life Sciences & Healthcare Innovation Program – Previously Recorded

    This program was targeted at innovative life science companies that have filed, or will soon file, NDA or 505(b)(2) applications and are anticipating their first Hatch-Waxman litigation.


Biotech + Breaking Glass: Leading Women in Life Sciences

View our latest episode

Four Decades Driving Innovation in Healthcare and Life Sciences

Cooley is a global leader in the industry

Read more

In the Moment + Up to Date

Join our list to receive updates when new content of interest to public company leaders is released

Subscribe Now

Cooley’s Life Sciences and Healthcare Innovation Program 2022

January program has been announced

Register now